Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CHILDHOOD-ONSET SCHIZOPHRENIA - AN OPEN-LABEL STUDY OF OLANZAPINE IN ADOLESCENTS
Autore:
KUMRA S; JACOBSEN LK; LENANE M; KARP BI; FRAZIER JA; SMITH AK; BEDWELL J; LEE P; MALANGA CJ; HAMBURGER S; RAPOPORT JI;
Indirizzi:
NIMH,CHILD PSYCHIAT BRANCH,BLDG 10,10 CTR DR MSC1600,ROOM 6N240 BETHESDA MD 20892 NINCDS BETHESDA MD 20892 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED BOSTON MA 00000
Titolo Testata:
Journal of the American Academy of Child and Adolescent Psychiatry
fascicolo: 4, volume: 37, anno: 1998,
pagine: 377 - 385
SICI:
0890-8567(1998)37:4<377:CS-AOS>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
OPEN TRIAL; CLOZAPINE; HALOPERIDOL; CHILDREN; DISORDER; PROGRESS;
Keywords:
OLANZAPINE; CLOZAPINE; CHILDHOOD-ONSET SCHIZOPHRENIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
S. Kumra et al., "CHILDHOOD-ONSET SCHIZOPHRENIA - AN OPEN-LABEL STUDY OF OLANZAPINE IN ADOLESCENTS", Journal of the American Academy of Child and Adolescent Psychiatry, 37(4), 1998, pp. 377-385

Abstract

Objective: Olanzapine, a potent 5-HT2a/2c, dopamine D1D2D4 antagonistwith anticholinergic activity, has a profile of known receptor affinity similar to that of clozapine. This pilot study examined the efficacy of olanzapine for treatment-refractory childhood-onset schizophreniain eight patients who had received 8-week open-label trials. For comparison, data are included from 15 patients who had received g-week open-label clozapine trials using identical rating instruments (largely by the same raters) in the same treatment setting. Method: Twenty-threechildren and adolescents with an onset of DSM-III-R schizophrenia by age 12 for whom at least two different typical neuroleptics had been ineffective participated in the two separate studies. Some of the patients were intolerant of clozapine, although it had been effective (n = 4). Patients receiving olanzapine were evaluated over 8 weeks with theBrief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms, the Scale for the Assessment of Negative Symptoms, and the Clinical Global Impressions Scale for Improvement. Results: For the eight patients who received olanzapine trials, at week 8 therewas a 17% improvement in the BPRS total score, a 27% improvement in the Scale for the Assessment of Negative Symptoms, and a 1% improvementin the Scale for the Assessment of Positive Symptoms, relative to ''ideal'' admission status on typical neuroleptics. In contrast, the magnitude of the effect sizes for each of the clinical ratings was larger at week 6 of the previous clozapine trial than for an 8-week olanzapine trial, relative to admission status on typical neuroleptics. For thefour children who had received both clozapine and olanzapine, BPRS total scores were significantly lower at week 6 of clozapine treatment compared with week 6 of olanzapine treatment (p = .03). Conclusion: These data provide preliminary evidence for the efficacy of olanzapine for some children and adolescents with treatment-refractory schizophrenia, but they also suggest the need for a more rigorous double-blind comparison of these two atypical antipsychotics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 02:09:38